Table 1: Clinical features of papillary thyroid carcinoma by gender.

Female ( )Male ( )Total ( ) value

Age 0.1934
TNM stage (II/III/IV)90/60/16527/27/66117/87/231
T1*128 (31.0%)26 (19.0%)154 (28.0%)
T2102 (24.7%)35 (25.5%)137 (24.9%)0.4023
T339 (9.4%)20 (14.6%)59 (10.7%)
T4144 (34.9%)56 (40.9%)200 (36.4)
Tumor size (cm) 0.0001
LN metastases38 (12.1%)15 (12.5%)53 (12.2%)
N1a13 (41.9%)3 (21.4%)16 (35.6%)0.1834
N1b18 (58.1%)11 (78.6%)29 (64.4%)
Soft-tissue invasion154 (48.9%)51 (42.5%)205 (47.1%)0.2328
Distant metastases14 (4.4%)13 (10.8%)27 (6.2%)0.0136
Multicentric92 (29.2%)30 (25.0%)122 (28.0%)0.3827
Aggressive histological patterns#8 (2.5%)7 (5.8%)15 (3.4%)0.1366
131I dose accumulative dose (mCi) 0.0023
Postoperative one month 131I uptake (%) 0.3018
Postoperative progression65 (20.6%)49 (40.8%)114 (26.2%)0.0001
Relapse/Residual33/3221/2854/600.4023
Period of relapse from diagnosis (year) 0.7132
Disease free94 (29.8%)27 (22.5%)121 (27.8%)0.1267
Followup period (yr) 0.3501
Cancer mortality26 (8.3%)29 (24.2%)55 (12.6%)0.0001

T1*: all the patients with local invasion or distant metastases.
Aggressive histological patterns#: tall cell, insular pattern, column cell, and poorly differentiated thyroid cancers.